United Arab Emirates Polymyositis Market Size & Outlook, 2026-2034


United Arab Emirates Polymyositis Market Insights

  • Based on Reed Intelligence findings, the United Arab Emirates Polymyositis Market reached USD 70.86 Million in 2025 and is estimated to attain USD 128.16 Million by 2034.
  • From 2026 to 2034, the United Arab Emirates market is expected to grow at a steady CAGR of 6.84%.
  • Within the Treatment Type category, Corticosteroids dominated in 2025 in terms of market size contribution.
  • Over the forecast period, Biologics is forecasted to deliver the fastest growth, positioning it as the most lucrative Treatment Type segment.

Other Key Findings


  • As of 2025, United Arab Emirates held 5.54% of the global Polymyositis Market size.
  • By 2034, United States is anticipated to capture the largest share of the global Polymyositis Market.
  • In Middle East and Africa, United Arab Emirates is expected to lead the regional Polymyositis Market size by 2034.
  • Egypt will remain the fastest-growing market in Middle East and Africa, reaching USD 30.22 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 70.86 Million
Market Size In 2034 USD 128.16 Million
Largest segment Corticosteroids
Units Revenue in USD Million
CAGR 6.84% (2026-2034)
Segmnetation Covered
Treatment Type
  1. Corticosteroids
  2. Immunosuppressants
  3. Biologics
  4. Others
Diagnosis Method
  1. Blood Tests
  2. Imaging Techniques
  3. Muscle Biopsy
  4. Electromyography
End-Use
  1. Hospitals
  2. Specialty Clinics
  3. Research Institutes
  4. Others
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends